AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 261 min read$GEHC

Lobo Kevin purchased $642K of GEHC

Lobo Kevin purchased 10,000 shares of GE HealthCare Technologies Inc. (GEHC) at $64.18 ($0.64M total) on 2026-05-22.

Original reporting
SEC EDGAR · Lobo Kevin
Published May 26, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 10:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GEHC
Bullish
medium confidence
Mentioned
$GEHC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GEHCBullishMed
01

Why it matters

The market may interpret the purchase as a positive signal, but without earnings, guidance, or deal details the effect is likely sentiment-driven rather than thesis-changing.

02

Market read

A director’s open-market buy in GEHC may provide a small sentiment tailwind, but it is not a standalone fundamental catalyst.

03

What to watch

Check for follow-on insider transactions, volume/price reaction around 2026-05-22, and whether other insiders simultaneously bought/sold.

Relevance 7/10Timing: Immediate (new SEC Form 4 disclosure dated 2026-05-26, covering trade on 2026-05-22).

Background

This is an SEC Form 4 insider transaction disclosure (director open-market purchase) for GE HealthCare Technologies.

Company-level read

Ticker impact

$GEHCBullishMedium confidence
Context

GE HealthCare director Lobo Kevin filed an open-market purchase of 10,000 shares at $64.18 on 2026-05-22.

Expected impact

Likely limited near-term impact; any move may fade unless followed by additional disclosures or fundamentals.

Evidence & confidence

The filing is a director open-market purchase with no 10b5-1 plan and a disclosed post-trade holding, but no new operating information is provided.

Market effects

Sector

Minimal; insider activity in one medtech/healthcare name typically does not reset sector expectations without accompanying company-specific news.

Regional

None indicated; disclosure is US-listed and does not reference regional operations.

Global

Low; no international deal/regulatory development mentioned.

Counterpoint

What could challenge this read

Open-market insider buys can be routine (tax/portfolio rebalancing) and may not reflect a new view on near-term fundamentals.

Key entities

  • issuer
    GE HealthCare Technologies Inc.

    Filed SEC Form 4 showing director Lobo Kevin purchased 10,000 shares on 2026-05-22.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GEHC insider trading history →

Related articles

OCT 7
$GEHCHighAI 9/10

GE HealthCare to acquire SOFIE Biosciences for $945 million, expanding U.S. PET supply footprint

GE HealthCare will acquire SOFIE Biosciences for $945 million in cash, expanding its U.S. PET radiopharmaceutical supply. The deal, expected to close in early 2027, will add SOFIE's 15 manufacturing sites and 21 cyclotrons to GE HealthCare's Pharmaceutical Diagnostics segment, enhancing its theranostics capabilities and access to high-growth areas. SOFIE's FAPI-74 radiopharmaceutical is in Phase III trials.

gmtoday.com2 min
OCT 7
$GEHCHighAI 9/10

GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million:

GE HealthCare agreed to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal, expected to close in early 2027, includes SOFIE's 15 U.S. manufacturing sites and rights to FAPI-74, an experimental PET imaging agent. SOFIE will continue serving existing customers post-acquisition. Trilantic North America, SOFIE's private equity backer, sold the company to GE HealthCare, which aims to expand its pharmaceutical diagnostics segment.

hedgeco.net2 min